feed,title,long_url,short_url
Benzinga,"KemPharm Amends Licensing Agreement With Gurnet Point Capital, Increases Milestone Payments To $590M",https://benzinga.com/general/biotech/21/04/20553449/kempharm-amends-licensing-agreement-with-gurnet-point-capital-increases-milestone-payments-to-590,https://j.mp/3wJsYsm
Benzinga,Greenwich LifeSciences' Stock Is Trading Higher After Breast Cancer Immunotherapy Shows 0% Recurrences Over 5 Years Follow-up,https://benzinga.com/general/biotech/21/04/20553341/greenwich-lifesciences-stock-is-trading-higher-after-breast-cancer-immunotherapy-shows-0-recurren,https://j.mp/3d4bGP3
